These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
136 related items for PubMed ID: 2298615
21. Radiosensitization of hypoxic cells in vivo by SR 2508 at low radiation doses: a preliminary report. Brown JM, Yu NY. Int J Radiat Oncol Biol Phys; 1984 Aug; 10(8):1207-12. PubMed ID: 6236184 [Abstract] [Full Text] [Related]
22. The effect of the hypoxic cell drug SR-4233 alone or combined with the ionizing radiations on two human tumor cell lines having different radiosensitivity. Lambin P, Guichard M, Chavaudra N, Malaise EP. Radiother Oncol; 1992 Jul; 24(3):201-4. PubMed ID: 1410575 [Abstract] [Full Text] [Related]
23. Second-generation 1,2,4-benzotriazine 1,4-di-N-oxide bioreductive anti-tumor agents: pharmacology and activity in vitro and in vivo. Minchinton AI, Lemmon MJ, Tracy M, Pollart DJ, Martinez AP, Tosto LM, Brown JM. Int J Radiat Oncol Biol Phys; 1992 Jul; 22(4):701-5. PubMed ID: 1544841 [Abstract] [Full Text] [Related]
24. Interaction of SR-4233 with hyperthermia and radiation in the FSaIIC murine fibrosarcoma tumor system in vitro and in vivo. Herman TS, Teicher BA, Coleman CN. Cancer Res; 1990 Aug 15; 50(16):5055-9. PubMed ID: 2379171 [Abstract] [Full Text] [Related]
25. Pharmacokinetics and bioreductive metabolism of the novel benzotriazine di-N-oxide hypoxic cell cytotoxin tirapazamine (WIN 59075; SR 4233; NSC 130181) in mice. Walton MI, Workman P. J Pharmacol Exp Ther; 1993 May 15; 265(2):938-47. PubMed ID: 8496834 [Abstract] [Full Text] [Related]
26. Evidence for a therapeutic gain when AQ4N or tirapazamine is combined with radiation. McKeown SR, Friery OP, McIntyre IA, Hejmadi MV, Patterson LH, Hirst DG. Br J Cancer Suppl; 1996 Jul 15; 27():S39-42. PubMed ID: 8763843 [Abstract] [Full Text] [Related]
27. Reoxygenation and rehypoxiation in the SCCVII mouse tumor. Kim IH, Brown JM. Int J Radiat Oncol Biol Phys; 1994 Jun 15; 29(3):493-7. PubMed ID: 8005805 [Abstract] [Full Text] [Related]
28. The effect of glutathione (GSH) depletion in vivo by buthionine sulfoximine (BSO) on the radiosensitization of SR 2508. Kramer RA, Soble M, Howes AE, Montoya VP. Int J Radiat Oncol Biol Phys; 1989 May 15; 16(5):1325-9. PubMed ID: 2523885 [Abstract] [Full Text] [Related]
29. Adaptation of human tumor cells to tirapazamine under aerobic conditions: implications of increased antioxidant enzyme activity to mechanism of aerobic cytotoxicity. Elwell JH, Siim BG, Evans JW, Brown JM. Biochem Pharmacol; 1997 Jul 15; 54(2):249-57. PubMed ID: 9271329 [Abstract] [Full Text] [Related]
30. Structure-activity relationships for benzotriazine di-N-oxides. Zeman EM, Baker MA, Lemmon MJ, Pearson CI, Adams JA, Brown JM, Lee WW, Tracy M. Int J Radiat Oncol Biol Phys; 1989 Apr 15; 16(4):977-81. PubMed ID: 2703405 [Abstract] [Full Text] [Related]
31. Radiosensitization of a mouse tumor model by sustained intra-tumoral release of etanidazole and tirapazamine using a biodegradable polymer implant device. Yapp DT, Lloyd DK, Zhu J, Lehnert S. Radiother Oncol; 1999 Oct 15; 53(1):77-84. PubMed ID: 10624857 [Abstract] [Full Text] [Related]
32. Putative electron-affinic radiosensitizers and markers of hypoxic tissue: Synthesis and preliminary in vitro biological characterization of C3-amino-substituted benzotriazine dioxides (BTDOs). Elsaidi HR, Yang XH, Ahmadi F, Weinfeld M, Wiebe LI, Kumar P. Eur J Med Chem; 2019 Mar 01; 165():216-224. PubMed ID: 30684798 [Abstract] [Full Text] [Related]
33. Radioresistance in murine solid tumors induced by interleukin-1. Braunschweiger PG, Basrur V, Santos O, Adessa A, Houdek P, Markoe AM. Radiat Res; 1996 Feb 01; 145(2):150-6. PubMed ID: 8606924 [Abstract] [Full Text] [Related]
34. Evaluation of hypoxic cell radio-sensitizers in terms of radio-sensitizing and repair-inhibiting potential. Dependency on p53 status of tumor cells and the effects on intratumor quiescent cells. Masunaga S, Uto Y, Nagasawa H, Hori H, Nagata K, Suzuki M, Kinashi Y, Ono K. Anticancer Res; 2006 Feb 01; 26(2A):1261-70. PubMed ID: 16619533 [Abstract] [Full Text] [Related]
35. Protection against SR 4233 (Tirapazamine) aerobic cytotoxicity by the metal chelators desferrioxamine and tiron. Herscher LL, Krishna MC, Cook JA, Coleman CN, Biaglow JE, Tuttle SW, Gonzalez FJ, Mitchell JB. Int J Radiat Oncol Biol Phys; 1994 Nov 15; 30(4):879-85. PubMed ID: 7960991 [Abstract] [Full Text] [Related]
36. The combined use of 131I-labeled antibody and the hypoxic cytotoxin SR 4233 in vitro and in vivo. Langmuir VK, Mendonca HL. Radiat Res; 1992 Dec 15; 132(3):351-8. PubMed ID: 1475358 [Abstract] [Full Text] [Related]
37. Radiosensitization in multifraction schedules. II. Greater sensitization by 2-nitroimidazoles than by oxygen. Taylor YC, Brown JM. Radiat Res; 1987 Oct 15; 112(1):134-45. PubMed ID: 3659294 [Abstract] [Full Text] [Related]
38. Enzymology of the reductive bioactivation of SR 4233. A novel benzotriazine di-N-oxide hypoxic cell cytotoxin. Walton MI, Workman P. Biochem Pharmacol; 1990 Jun 01; 39(11):1735-42. PubMed ID: 2344370 [Abstract] [Full Text] [Related]
39. In vitro activity of the benzotriazine dioxide SR 4233 against human tumour colony-forming units. Hanauske AR, Ross M, Degen D, Hilsenbeck SG, Von Hoff DD. Eur J Cancer; 1993 Jun 01; 29A(3):423-5. PubMed ID: 8398345 [Abstract] [Full Text] [Related]
40. Combined effects of tirapazamine and mild hyperthermia on anti-angiogenic agent (TNP-470) treated tumors-reference to the effect on intratumor quiescent cells. Masunaga S, Ono K, Nishimura Y, Kanamori S, Saga T, Suzuki M, Kinashi Y, Takagaki M, Kasai S, Nagasawa H, Uto Y, Hori H. Int J Radiat Oncol Biol Phys; 2000 Jun 01; 47(3):799-807. PubMed ID: 10837967 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]